Seven earnings reports that matter

Seven earnings reports that matter
Looking to cut through the earnings fat to get to the meat? Here are the coming week's top reports.
January 17, 2003: 11:28 AM EST
By Justin Lahart, CNN/Money Staff Writer
NEW YORK (CNN/Money) - You might not know it from the way the market's been shaking, but the fourth-quarter earnings period is going well, Microsoft notwithstanding.
"So far, so good," First Call analyst Ken Perkins said. "The preannouncement season was better than we thought it was going to be and the numbers are coming in relatively well."
Of the companies in the S&P 500, 95 have reported so far, and on average they are reporting fourth-quarter earnings that are 9.8 percent higher than last year and 3.7 percent better than analysts expected.
But there is much more to come -- particularly in the coming week when a bevy of companies are due to report. If you're a day trader, you'll want to keep an eye on all of them. If not, you can focus on these seven reports that matter and let the rest of the earnings noise pass you by.
Companies in this report: Ford; Citigroup; 3M; Pfizer; J.P. Morgan; Tyco; McDonald's.
Ford
The last few years have badly hurt Ford (F: Research, Estimates), which reports results before the bell Tuesday.
Its balance sheet damaged by an underfundeded pension fund, still smarting from former CEO Jacques Nasser's mishandling of the Firestone crisis and heavily in debt, Ford has been severely cut up. In October, its stock plummeted and the yield on its bonds spiked to distressing levels -- a sign that investors were questioning its solvency.
Ford's share of the U.S. market shrank last year and its biggest rival, General Motors (GM: Research, Estimates), smelled blood in the water. Sure, the No. 1 auto maker's generous incentive programs are aimed at maintaining sales in a tough economy, but they have had the added benefit of hitting Ford, the No. 2 auto maker, when it's down.
It looks like the worst may be behind Ford, but slowing consumer-spending growth in the coming year could open the old wounds again. And investors still don't know what to think of Bill Ford, the company's CEO. Ford's heart seems to be in the right place -- as a member of the automaker's founding family he is focused on its long-term health. But does that mean he lacks appropriate focus on day-to-day operations?
Why it matters: Ford's health, or lack thereof, is a barometer for the health of the entire manufacturing sector. If it can get back on the road to Wellville it would signal health for the entire economy.
Analysts surveyed by Multex think Ford earned 7 cents in the fourth quarter.
Citigroup
With limited exposure to the likes of Enron and WorldCom, Citigroup (C: Research, Estimates), which reports ahead of the open Tuesday, has weathered the tough economy much better than J.P. Morgan, its closest competitor (see below).
But boy, has it been exposed to the storm over Wall Street. Jack Grubman, a former telecom analyst at Citi's Salomon Smith Barney brokerage unit, has been accused of hyping stocks in order to win investment banking deals for the firm. CEO Sandy Weill was pulled into the fray in the fall when it emerged that he had asked Grubman to take a "fresh look" at AT&T's stock. Grubman said in an e-mail that his children were, thanks to Weill's efforts, admitted to the prestigious nursery school at New York's 92nd Street Y after he upgraded AT&T stock in 1999.
In a settlement agreed to last month, Wall Street firms are to pay about $1.5 billion to end the investigation into charges that analysts issued glowing reports to win lucrative banking business for their firms. Citi will pay $400 million of that -- more than any other firm. A final settlement has been delayed as regulators hammer out details.
Critics say that the regulatory mess has taken Weill's focus away from his job of running the bank, and that Bank One, run by his former protege Jamie Dimon, is where the future is. Investors want to know if Weill's got his eye back on the ball, or if he should be led out to pasture.
Why it matters: The nation's largest bank, Citi is a proxy for the health of the entire U.S. financial system. Also, if it is losing focus, that could signal a profound shift in the banking sector.
Analysts expect Citi earned 46 cents a share in the fourth quarter, down from last year's 74 cents.
3M
By all rights 3M (MMM: Research, Estimates), the Minnesota-based industrial company known for its abrasives, adhesives and Post-it Notes, should be in a deep funk. What other business is so leveraged to the skulking global economy? Yet the company, which is due to report before Tuesday's open, has weathered the downturn remarkably well, with sales and earnings losing only a bit of ground in 2001, and then making it back up in 2002.
Its stock is up 28 percent from where it was three years ago -- one of just four Dow Jones industrial average components to gain since the index hit its January 2000 peak.
Why it matters: Because so many manufacturers use what it sells, 3M is seen as a good barometer for the overall economy. Despite its relatively good results through the downturn, it has consistently struck a cautious note. Any sign that this caution is receding could sound the all-clear signal on the economy.
Analysts think 3M earned $1.28 a share in the fourth quarter, compared with 98 cents in the year-earlier period.
Pfizer
Shares of Pfizer (PFE: Research, Estimates), the big drugmaker set to report before the open Wednesday, have been under the weather, struggling since it announced in July that it would buy rival Pharmacia (PHA: Research, Estimates).
Part of this is related to arbitragers, who have sold Pfizer shares short and bought Pharmacia shares in expectation that when the merger does go through they'll make a profit. With the merger expected to be completed this quarter, this is an overhang that should be cleared away shortly.
But Pfizer also is suffering from problems similar to many of its peers: Its pipeline of new drugs is limited, and with patent expirations on a number of its current products coming up, competition from generic manufactures looms. Already, Pfizer is locked in a court battle over the impending generic release of anticonvulsant Neurontin.
Why it matters: Pfizer may be an example of investors ignoring the forest for the trees. The arbitrage play and worries about generics aside, it continues to offer something that many other companies have not -- earnings and revenue that have grown throughout the economic downturn and which are expected to continue to grow through the coming year.
Analysts think Pfizer earned 47 cents a share in the fourth quarter, compared with 34 cents a year ago.
J.P. Morgan Chase
It's been a tumultuous time for J.P. Morgan Chase (JPM: Research, Estimates), due to report ahead of the bell Wednesday. Heavily exposed to Kmart, Global Crossing, Argentina and, especially, Enron, the bank has taken mighty losses over the past year. Nor is the trouble over just yet -- there may not be any more Enrons out there, but the bank's exposure to other troubled energy firms is a cause for concern.
The book on Enron, at least, appears to have closed. Earlier this month the bank said it would take a $400 million charge related to the settlement of an Enron-related surety bond dispute with insurers. It said it would take an additional charge of $900 million to pay for other lawsuits over the bank's dealings with Enron and to settle charges of conflicts of interest on Wall Street.
Why it matters: Some companies are good barometers of the health of a specific sector or the economy at large; J.P. Morgan is an indicator of the stupidity bankers will stoop to during an investing bubble. The sooner J.P. Morgan sorts through the aftereffects of its past mistakes, the sooner the post-bubble hangover will go away for all of us.
Analysts expect J.P. Morgan lost 7 cents a share in the fourth quarter, compared with a year-ago gain of 12 cents.
Tyco
Amazing to think it's been just a year since Tyco (TYC: Research, Estimates), due to report Wednesday, began to fall apart.
Let's review: Critics have long said there was something fishy about Tyco's results, but investors didn't care -- so long as the company kept on posting its market-pleasing profits. But when it reported its fourth-quarter 2001 earnings last January, it said its first-quarter earnings would miss estimates. The deal was off, as far as the market was concerned, and Tyco shares fell 8.3 percent. They would fall much more in the weeks and months to come.
A rushed breakup plan that later was abandoned, the resignation of CEO Dennis Kozlowski, zillion-dollar umbrella stands, lewd ice sculptures -- there's something to be said for a company that can make its way to the front page of the New York Post. But with new CEO Ed Breen, Tyco appears to be in steadier hands. Though nowhere near its old highs, its stock has climbed steadily since the summer.
Why it matters: Tyco has become a battleground between investors, who feel that the company which, after all, runs real businesses, is a deep value, and critics (aka short sellers) who think there is more pain to come. Who is right will depend on whether Tyco can get profit growth moving again. It is heavily indebted and will have trouble paying off creditors if it cannot do that.
Analysts expect Tyco made 32 cents a share in its latest quarter, compared with 73 cents in the year-ago period.
McDonald's
McDonald's (MCD: Research, Estimates), due to report results ahead of Thursday's open, has been through the grinder.
A weak global economy, along with persistent worries abroad over mad cow disease, have hurt sales badly. Rather than luring customers back, price cuts have mostly just cut into profits. CEO Jack Greenberg announced his retirement in December, shortly after the hamburger chain warned of lower profits again.
Why it matters: McDonald's ain't exactly Le Cirque: when people stop stopping by the golden arches, it says something about the consumer.
Analysts expect McDonald's earned 25 cents a share in the fourth quarter, compared with the previous year's 34 cents.
Looking to cut through the earnings fat to get to the meat? Here are the coming week's top reports.
January 17, 2003: 11:28 AM EST
By Justin Lahart, CNN/Money Staff Writer
NEW YORK (CNN/Money) - You might not know it from the way the market's been shaking, but the fourth-quarter earnings period is going well, Microsoft notwithstanding.
"So far, so good," First Call analyst Ken Perkins said. "The preannouncement season was better than we thought it was going to be and the numbers are coming in relatively well."
Of the companies in the S&P 500, 95 have reported so far, and on average they are reporting fourth-quarter earnings that are 9.8 percent higher than last year and 3.7 percent better than analysts expected.
But there is much more to come -- particularly in the coming week when a bevy of companies are due to report. If you're a day trader, you'll want to keep an eye on all of them. If not, you can focus on these seven reports that matter and let the rest of the earnings noise pass you by.
Companies in this report: Ford; Citigroup; 3M; Pfizer; J.P. Morgan; Tyco; McDonald's.
Ford
The last few years have badly hurt Ford (F: Research, Estimates), which reports results before the bell Tuesday.
Its balance sheet damaged by an underfundeded pension fund, still smarting from former CEO Jacques Nasser's mishandling of the Firestone crisis and heavily in debt, Ford has been severely cut up. In October, its stock plummeted and the yield on its bonds spiked to distressing levels -- a sign that investors were questioning its solvency.
Ford's share of the U.S. market shrank last year and its biggest rival, General Motors (GM: Research, Estimates), smelled blood in the water. Sure, the No. 1 auto maker's generous incentive programs are aimed at maintaining sales in a tough economy, but they have had the added benefit of hitting Ford, the No. 2 auto maker, when it's down.
It looks like the worst may be behind Ford, but slowing consumer-spending growth in the coming year could open the old wounds again. And investors still don't know what to think of Bill Ford, the company's CEO. Ford's heart seems to be in the right place -- as a member of the automaker's founding family he is focused on its long-term health. But does that mean he lacks appropriate focus on day-to-day operations?
Why it matters: Ford's health, or lack thereof, is a barometer for the health of the entire manufacturing sector. If it can get back on the road to Wellville it would signal health for the entire economy.
Analysts surveyed by Multex think Ford earned 7 cents in the fourth quarter.
Citigroup
With limited exposure to the likes of Enron and WorldCom, Citigroup (C: Research, Estimates), which reports ahead of the open Tuesday, has weathered the tough economy much better than J.P. Morgan, its closest competitor (see below).
But boy, has it been exposed to the storm over Wall Street. Jack Grubman, a former telecom analyst at Citi's Salomon Smith Barney brokerage unit, has been accused of hyping stocks in order to win investment banking deals for the firm. CEO Sandy Weill was pulled into the fray in the fall when it emerged that he had asked Grubman to take a "fresh look" at AT&T's stock. Grubman said in an e-mail that his children were, thanks to Weill's efforts, admitted to the prestigious nursery school at New York's 92nd Street Y after he upgraded AT&T stock in 1999.
In a settlement agreed to last month, Wall Street firms are to pay about $1.5 billion to end the investigation into charges that analysts issued glowing reports to win lucrative banking business for their firms. Citi will pay $400 million of that -- more than any other firm. A final settlement has been delayed as regulators hammer out details.
Critics say that the regulatory mess has taken Weill's focus away from his job of running the bank, and that Bank One, run by his former protege Jamie Dimon, is where the future is. Investors want to know if Weill's got his eye back on the ball, or if he should be led out to pasture.
Why it matters: The nation's largest bank, Citi is a proxy for the health of the entire U.S. financial system. Also, if it is losing focus, that could signal a profound shift in the banking sector.
Analysts expect Citi earned 46 cents a share in the fourth quarter, down from last year's 74 cents.
3M
By all rights 3M (MMM: Research, Estimates), the Minnesota-based industrial company known for its abrasives, adhesives and Post-it Notes, should be in a deep funk. What other business is so leveraged to the skulking global economy? Yet the company, which is due to report before Tuesday's open, has weathered the downturn remarkably well, with sales and earnings losing only a bit of ground in 2001, and then making it back up in 2002.
Its stock is up 28 percent from where it was three years ago -- one of just four Dow Jones industrial average components to gain since the index hit its January 2000 peak.
Why it matters: Because so many manufacturers use what it sells, 3M is seen as a good barometer for the overall economy. Despite its relatively good results through the downturn, it has consistently struck a cautious note. Any sign that this caution is receding could sound the all-clear signal on the economy.
Analysts think 3M earned $1.28 a share in the fourth quarter, compared with 98 cents in the year-earlier period.
Pfizer
Shares of Pfizer (PFE: Research, Estimates), the big drugmaker set to report before the open Wednesday, have been under the weather, struggling since it announced in July that it would buy rival Pharmacia (PHA: Research, Estimates).
Part of this is related to arbitragers, who have sold Pfizer shares short and bought Pharmacia shares in expectation that when the merger does go through they'll make a profit. With the merger expected to be completed this quarter, this is an overhang that should be cleared away shortly.
But Pfizer also is suffering from problems similar to many of its peers: Its pipeline of new drugs is limited, and with patent expirations on a number of its current products coming up, competition from generic manufactures looms. Already, Pfizer is locked in a court battle over the impending generic release of anticonvulsant Neurontin.
Why it matters: Pfizer may be an example of investors ignoring the forest for the trees. The arbitrage play and worries about generics aside, it continues to offer something that many other companies have not -- earnings and revenue that have grown throughout the economic downturn and which are expected to continue to grow through the coming year.
Analysts think Pfizer earned 47 cents a share in the fourth quarter, compared with 34 cents a year ago.
J.P. Morgan Chase
It's been a tumultuous time for J.P. Morgan Chase (JPM: Research, Estimates), due to report ahead of the bell Wednesday. Heavily exposed to Kmart, Global Crossing, Argentina and, especially, Enron, the bank has taken mighty losses over the past year. Nor is the trouble over just yet -- there may not be any more Enrons out there, but the bank's exposure to other troubled energy firms is a cause for concern.
The book on Enron, at least, appears to have closed. Earlier this month the bank said it would take a $400 million charge related to the settlement of an Enron-related surety bond dispute with insurers. It said it would take an additional charge of $900 million to pay for other lawsuits over the bank's dealings with Enron and to settle charges of conflicts of interest on Wall Street.
Why it matters: Some companies are good barometers of the health of a specific sector or the economy at large; J.P. Morgan is an indicator of the stupidity bankers will stoop to during an investing bubble. The sooner J.P. Morgan sorts through the aftereffects of its past mistakes, the sooner the post-bubble hangover will go away for all of us.
Analysts expect J.P. Morgan lost 7 cents a share in the fourth quarter, compared with a year-ago gain of 12 cents.
Tyco
Amazing to think it's been just a year since Tyco (TYC: Research, Estimates), due to report Wednesday, began to fall apart.
Let's review: Critics have long said there was something fishy about Tyco's results, but investors didn't care -- so long as the company kept on posting its market-pleasing profits. But when it reported its fourth-quarter 2001 earnings last January, it said its first-quarter earnings would miss estimates. The deal was off, as far as the market was concerned, and Tyco shares fell 8.3 percent. They would fall much more in the weeks and months to come.
A rushed breakup plan that later was abandoned, the resignation of CEO Dennis Kozlowski, zillion-dollar umbrella stands, lewd ice sculptures -- there's something to be said for a company that can make its way to the front page of the New York Post. But with new CEO Ed Breen, Tyco appears to be in steadier hands. Though nowhere near its old highs, its stock has climbed steadily since the summer.
Why it matters: Tyco has become a battleground between investors, who feel that the company which, after all, runs real businesses, is a deep value, and critics (aka short sellers) who think there is more pain to come. Who is right will depend on whether Tyco can get profit growth moving again. It is heavily indebted and will have trouble paying off creditors if it cannot do that.
Analysts expect Tyco made 32 cents a share in its latest quarter, compared with 73 cents in the year-ago period.
McDonald's
McDonald's (MCD: Research, Estimates), due to report results ahead of Thursday's open, has been through the grinder.
A weak global economy, along with persistent worries abroad over mad cow disease, have hurt sales badly. Rather than luring customers back, price cuts have mostly just cut into profits. CEO Jack Greenberg announced his retirement in December, shortly after the hamburger chain warned of lower profits again.
Why it matters: McDonald's ain't exactly Le Cirque: when people stop stopping by the golden arches, it says something about the consumer.
Analysts expect McDonald's earned 25 cents a share in the fourth quarter, compared with the previous year's 34 cents.